{"doc_id": "eanm__v00000000", "chunk_id": "000000", "text": "# EANM", "section": "EANM", "page_from": null, "page_to": null, "display_name": "EANM", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "3a163ed10298df0795339f21e2c87f332ce14032deef76c1764739e526e15ff7"}
{"doc_id": "eanm__v00000000", "chunk_id": "000001", "text": "https://doi.org/10.1007/s00259-021-05450-9\nGUIDELINES\nEANM guideline on the role of 2‑[18F]FDG PET/CT in diagnosis, staging,\nprognostic value, therapy assessment and restaging of ovarian cancer,\nendorsed by the American College of Nuclear Medicine (ACNM),\nthe Society of Nuclear Medicine and Molecular Imaging (SNMMI)\nand the International Atomic Energy Agency (IAEA)\nRoberto C. Delgado Bolton1   · Nicolas Aide2,3   · Patrick M. Colletti4   · Annamaria Ferrero5   · Diana Paez6   ·\nAndrea Skanjeti7   · Francesco Giammarile6,8 \nReceived: 5 May 2021 / Accepted: 3 June 2021\n© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021\nAbstract\nIn most patients with ovarian carcinoma, the diagnosis is reached when the disease is long past the initial stages, presenting already an\nadvanced stage, and they usually have a very bad prognosis. Cytoreductive or debulking surgical procedures, platinum-based chemotherapy\nand targeted agents are key therapeutic elements. However, around 7 out of 10 patients present recurrent disease within 36 months from", "section": "GUIDELINES", "page_from": 1, "page_to": 1, "display_name": "EANM", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "4027409ac7ad35c2c009fc933d22c68e86caf1d156a73105c4a434a0b78d20af"}
{"doc_id": "eanm__v00000000", "chunk_id": "000002", "text": "and targeted agents are key therapeutic elements. However, around 7 out of 10 patients present recurrent disease within 36 months from\nthe initial diagnosis. The metastatic spread in ovarian cancer follows three pathways: contiguous dissemination across the peritoneum,\ndissemination through the lymphatic drainage and, although less importantly in this case, through the bloodstream. Radiological imaging,\nincluding ultrasound, CT and MRI, are the main imaging techniques in which management decisions are supported, CT being considered\nthe best available technique for presurgical evaluation and staging purposes. Regarding 2-[18F]FDG PET/CT, the evidence available in the\nliterature demonstrates efficacy in primary detection, disease staging and establishing the prognosis and especially for relapse detection.\nThere is limited evidence when considering the evaluation of therapeutic response. This guideline summarizes the level of evidence and\ngrade of recommendation for the clinical indications of 2-[18F]FDG PET/CT in each disease stage of ovarian carcinoma.\nKeywords  Ovarian cancer · Imaging · PET/CT · 18F-FDG · Guideline · Clinical indications\nAbbreviations\n2-[18F]FDG", "section": "GUIDELINES", "page_from": 1, "page_to": 1, "display_name": "EANM", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "98ef11f4077839efdb4b191a25dd1e1c1ef6dc531f9db4a1bc4b3388ea372a1e"}
{"doc_id": "eanm__v00000000", "chunk_id": "000003", "text": "Keywords  Ovarian cancer · Imaging · PET/CT · 18F-FDG · Guideline · Clinical indications\nAbbreviations\n2-[18F]FDG\n\u00072-[18F]Fluoro-2-deoxy-D-glucose\nAOC\n\u0007Advanced ovarian cancer\nBOT\n\u0007Borderline ovarian tumour\nCEA\n\u0007Serum carcinoembryonic antigen\nCT\n\u0007Computed tomography\nceCT\n\u0007Contrast-enhanced computed\ntomography\nEOC\n\u0007Early-stage ovarian carcinoma\nEORTC​\n\u0007European Organisation for Research\nand Treatment of Cancer\nESMO\n\u0007European Society of Medical Oncology\nESGO\n\u0007European Society of Gynaecological\nOncology\nFIGO\n\u0007International Federation of Gynaecol-\nogy and Obstetrics\nIAEA\n\u0007International Atomic Energy Agency\nIOTA\n\u0007International Ovarian Tumour Analysis\ngroup\nLBM\n\u0007Lean body mass\nLGSC\n\u0007Low-grade serous carcinoma\nPCI\n\u0007Peritoneal cancer index\nPET\n\u0007Positron emission tomography\nMATV or MTV\n\u0007Metabolic active tumour volume\nMRI\n\u0007Magnetic resonance imaging\nsBOT(s)\n\u0007Serous borderline ovarian tumour(s)\nParticipating associations  EANM: Roberto C. Delgado Bolton,\nNicolas Aide, and Francesco Giammarile\nIAEA: Francesco Giammarile and Diana Paez\nACNM and SNMMI: Patrick M. Colletti\nEndorsements  IAEA: endorsed 04/2021\nACNM: endorsed 04/2021\nSNMMI: endorsed 04/2021", "section": "GUIDELINES", "page_from": 1, "page_to": 1, "display_name": "EANM", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "0b65b212a676cd64e20fa6cdd7d7575e58caa2d5aaac143cacc9097880197502"}
{"doc_id": "eanm__v00000000", "chunk_id": "000004", "text": "IAEA: Francesco Giammarile and Diana Paez\nACNM and SNMMI: Patrick M. Colletti\nEndorsements  IAEA: endorsed 04/2021\nACNM: endorsed 04/2021\nSNMMI: endorsed 04/2021\nThis article is part of the Topical Collection on Oncology -\nGenitourinary\n *\t Roberto C. Delgado Bolton\n\nrbiolton@gmail.com\nExtended author information available on the last page of the article\n/ Published online: 3 July 2021\nEuropean Journal of Nuclear Medicine and Molecular Imaging (2021) 48:3286–3302\n1 3", "section": "GUIDELINES", "page_from": 1, "page_to": 1, "display_name": "EANM", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "35d67464c3d42e612ab262069dbec7c2b94d4e5fbd4d2f7b33ac0088a9e20996"}
{"doc_id": "eanm__v00000000", "chunk_id": "000005", "text": "SUL\n\u0007Standardized uptake value using lean\nbody mass (LBM)\nSUV\n\u0007Standardized uptake value\nTAUS\n\u0007Transabdominal ultrasound\nTLG\n\u0007Total lesion glycolysis\nTVUS\n\u0007Transvaginal ultrasound\nUS\n\u0007Ultrasound or echography\nVOI\n\u0007Volume of interest\nWHO\n\u0007World Health Organization\nPreamble\nThe European Association of Nuclear Medicine (EANM)\nis a professional non-profit medical association that facili-\ntates communication worldwide among individuals pursu-\ning clinical and research excellence in nuclear medicine.\nThe EANM was founded in 1985.\nThese guidelines are intended to assist practitioners in provid-\ning appropriate nuclear medicine care for patients. They are not\ninflexible rules or requirements of practice and are not intended,\nnor should they be used, to establish a legal standard of care.\nThe ultimate judgement regarding the propriety of any specific pro-\ncedure or course of action must be made by medical professionals tak-\ning into account the unique circumstances of each case. Thus, there is\nno implication that an approach differing from the guidelines, standing\nalone, is below the standard of care. To the contrary, a conscientious", "section": "SUL", "page_from": 2, "page_to": 2, "display_name": "EANM", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "f0b490352434481a746d9ac1a6cbc3d9804033f2c8bbb1f3d3620a2c0790a54a"}
{"doc_id": "eanm__v00000000", "chunk_id": "000006", "text": "no implication that an approach differing from the guidelines, standing\nalone, is below the standard of care. To the contrary, a conscientious\npractitioner may responsibly adopt a course of action different from that\nset out in the guidelines when, in the reasonable judgement of the prac-\ntitioner, such course of action is indicated by the condition of the patient,\nlimitations of available resources or advances in knowledge or technol-\nogy subsequent to publication of the guidelines.\nThe practice of medicine involves not only the science\nbut also the art of dealing with the prevention, diagnosis,\nalleviation and treatment of disease.\nThe variety and complexity of human conditions make it\nimpossible to always reach the most appropriate diagnosis or to\npredict with certainty a particular response to treatment. There-\nfore, it should be recognized that adherence to these guidelines\nwill not ensure an accurate diagnosis or a successful outcome.\nAll that should be expected is that the practitioner will follow a\nreasonable course of action based on current knowledge, avail-\nable resources and the needs of the patient to deliver effective", "section": "SUL", "page_from": 2, "page_to": 2, "display_name": "EANM", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "e44f700a91a51b2e494ac84c0661dfb1a8bd35815c9b3bec754ad1519d2a7488"}
{"doc_id": "eanm__v00000000", "chunk_id": "000007", "text": "All that should be expected is that the practitioner will follow a\nreasonable course of action based on current knowledge, avail-\nable resources and the needs of the patient to deliver effective\nand safe medical care. The sole purpose of these guidelines is to\nassist practitioners in achieving this objective.\nIntroduction\nIn most patients with ovarian carcinoma, the diagnosis is\nreached when the disease is long past the initial stages,\npresenting already an advanced stage, and they usually\nhave a very bad prognosis. Radiological imaging, includ-\ning ultrasound, CT and MRI, are the main imaging tech-\nniques in which management decisions are supported.\nRegarding 2-[18F]FDG PET/CT, the evidence available\nin the literature demonstrates efficacy in primary detec-\ntion, disease staging and establishing the prognosis and\nespecially for relapse detection. There is limited evidence\nwhen considering the evaluation of therapeutic response.\nThis guideline summarizes the level of evidence and grade\nof recommendation for the clinical indications of 2-[18F]\nFDG PET/CT in each disease stage of ovarian carcinoma.\nBackground\nEpidemiology\nWorldwide data shows that ovarian tumours are among those", "section": "SUL", "page_from": 2, "page_to": 2, "display_name": "EANM", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "9e6087ed37dcd83f20b43a83ecd69070abbbfffe1f5a59ba113cabb8cdae698a"}
{"doc_id": "eanm__v00000000", "chunk_id": "000008", "text": "of recommendation for the clinical indications of 2-[18F]\nFDG PET/CT in each disease stage of ovarian carcinoma.\nBackground\nEpidemiology\nWorldwide data shows that ovarian tumours are among those\nwith high incidence (seventh largest) and are responsible\nfor a high number of cancer-related deaths (eighth highest)\n[1–3]. Although global incidence rates remain stable over\ntime, in some Eastern Europeans countries, its incidence is\nthe highest [1], and in South-Central Asia, this tumour is the\nthird cause in cancer-related deaths [4]. Globally, 295,400\nestimated new cases and 184,800 cancer-related deaths were\ndescribed in 2018. In the USA, based on the National Can-\ncer Institute’s Surveillance, Epidemiology, and End Results\n(SEER) program statistics for 2017 [4], there were 11.7 new\novarian cancer cases per 100,000 women per year, and there\nwere 7.4 ovarian cancer-related deaths per 100,000 women\nper year. The European Cancer Information System esti-\nmated 45,694 new cases with 32,250 deaths from ovarian\ncancer in 40 European countries for the year 2018 [5].\nMoreover, the survival of the patients is highly impacted\nby the staging. A recent study based on SEER’s database", "section": "SUL", "page_from": 2, "page_to": 2, "display_name": "EANM", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "d061765fbd1521e7113aa87402b5e84dfbf6e1bb8cabf9baa9d13175d5963aed"}
{"doc_id": "eanm__v00000000", "chunk_id": "000009", "text": "cancer in 40 European countries for the year 2018 [5].\nMoreover, the survival of the patients is highly impacted\nby the staging. A recent study based on SEER’s database\nshowed a dramatic difference in the 5-year survival of\npatients with localized disease in comparison to patients\nwith distant dissemination (88.5% versus 37.4%, respec-\ntively) for those diagnosed in 2010–2014, being even more\nimpressive in women diagnosed in the 1990s [6].\nPathology\nAn epithelial origin is present in over 90% of malignant\novarian tumours. This pathologic type includes different\nhistologic non-homogeneous types. Traditionally, patholo-\ngists have classified ovarian carcinoma into the following\nsubtypes:\n•\t Serous: it represents the most frequent type of advanced\novarian cancers (70–80%).\n3287\nEuropean Journal of Nuclear Medicine and Molecular Imaging  (2021) 48:3286–3302\n123456789)\n1 3", "section": "SUL", "page_from": 2, "page_to": 2, "display_name": "EANM", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "df0b21f94124649d7b24f8b01bca11486be3c394d92d115a7821213c4d19b68c"}
{"doc_id": "eanm__v00000000", "chunk_id": "000010", "text": "•\t Endometrioid: account for around 10–20% of ovarian\ncancers.\n•\t Clear-cell: account for around 5–10% of ovarian cancers.\n•\t Mucinous.\n•\t Transitional cell.\n•\t Mixed epithelial tumours.\n•\t Undifferentiated tumours.\nBorderline tumours represent a grey area, neither benign\nnor malignant, and account for 10–15% of ovarian tumours.\nRegarding the frequency of the mentioned subtypes, there\nare huge differences when comparing early-stage tumours\n(clear predominance of non-serous subtypes) and advanced\nstage tumours (predominance of serous subtype) [7].\nWhen analysing together the histopathology and molecu-\nlar genetics, ovarian tumours are currently classified in 5\ncategories: high-grade serous (70%), endometrioid (20%),\nclear-cell (10%), mucinous (3%) and low-grade serous car-\ncinomas (< 5%). The 5 categories represent clearly different\ntumours, with different genetic risk factors, epidemiological\ndifferences, differences in premalignant or precursor lesions,\ndifferent spreading patterns, response to chemotherapy and\nprognosis. Moreover, a relevant proportion of tumours that\nwere classified as primary ovarian carcinomas (especially", "section": "SUL", "page_from": 3, "page_to": 3, "display_name": "EANM", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "db4e0ae228f218d3f30befad0e04d6e6b6b5537d7a1dab48b38f5f487fc7dcd8"}
{"doc_id": "eanm__v00000000", "chunk_id": "000011", "text": "different spreading patterns, response to chemotherapy and\nprognosis. Moreover, a relevant proportion of tumours that\nwere classified as primary ovarian carcinomas (especially\nserous, endometrioid and clear-cell carcinomas) were in fact\nprimary tumours of the fallopian tube and the endometrium,\naffecting in a second stage the ovary [8].\nThe last revision of the ovarian cancer World Health Organi-\nzation (WHO) classification dates back 2014. Both the WHO\nclassification (categorizing histopathologic and molecular\ntumour types) and the International Federation of Gynaecol-\nogy and Obstetrics (FIGO) classification (classifying different\ntumour stages) are the basis of the therapeutic management\ndecisions and the most precise when evaluating prognosis.\nRegarding molecular genetics, BRCA1 and BRCA2\n(abbreviation for BReast CAncer gene) are tumour sup-\npressor genes that impact the chances of developing can-\ncer, helping repair DNA disruptions that can lead to cancer\nand the uncontrolled growth of tumours. TP53 mutations\nare identified in most (96%) high-grade serous carcinomas.\nEarly p53 loss followed by BRCA loss generates deficiency", "section": "SUL", "page_from": 3, "page_to": 3, "display_name": "EANM", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "dc63fdd7b1a21e2d504a8ea92330860fe18fdd7bd2c8e4bdff7d3442cafa78bf"}
{"doc_id": "eanm__v00000000", "chunk_id": "000012", "text": "and the uncontrolled growth of tumours. TP53 mutations\nare identified in most (96%) high-grade serous carcinomas.\nEarly p53 loss followed by BRCA loss generates deficiency\nin homologous recombination repair, which in turn sets off\nchromosomal instability and extensive somatic copy number\nchanges. This is an example of recent advances in molecular\npathology, which have greatly improved the understanding\nof the biology of ovarian carcinomas and evolved patient\nmanagement [9].\nPatterns of spread\nMetastatic spread in ovarian cancer typically follows\nthree different routes: (a) by contiguity to the peritoneum,\n(b) lymphatic dissemination and (c) haematogenous\ndissemination.\n•\t Dissemination by contiguity in ovarian cancer makes the\nperitoneum the most affected tissue because in normal\nconditions the circulation of peritoneal fluid carries ovar-\nian cells. In the first step, the primary ovarian tumour lib-\nerates malignant cells into the peritoneum, where these\ncells are incorporated into the peritoneal fluid normal\nflow inside the peritoneal cavity that takes them towards\nthe upper abdominal quadrants. The normal physiology\nof the peritoneal fluid flow is based on the changes in", "section": "SUL", "page_from": 3, "page_to": 3, "display_name": "EANM", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "919a5e42c58e7cd935b65425ae3f31d3e33f4843ac96404006328f387e3f7363"}
{"doc_id": "eanm__v00000000", "chunk_id": "000013", "text": "flow inside the peritoneal cavity that takes them towards\nthe upper abdominal quadrants. The normal physiology\nof the peritoneal fluid flow is based on the changes in\nthe subphrenic pressures generated due to the respiratory\nmovements, oscillating between the negative and positive\nvalues. These pressure oscillations drive the peritoneal\nfluid from the paracolic channels cranially to the right\nsubhepatic area and the right subdiaphragmatic area\n[10]. Ovarian cancer typically disseminates by contigu-\nity to the greater omentum, paracolic channels, Douglas’\npouch, perihepatic region (particularly affecting the glis-\nsonian capsule), diaphragmatic and bowel surface and,\nless frequently, mesentery, splenic surface, porta hepatis\nand gastrosplenic ligament. Macroscopically, peritoneal\ninvolvement usually presents as nodules, fusiform lesions\nor plaques consisting of soft tissue and affecting the peri-\ntoneal (parietal or visceral) walls. In the case of serous\ntumours, they appear as very small calcified lesions.\n•\t Lymphatic dissemination may circulate through three\nalternative pathways: (a) following the ovarian lym-\nphatic vessels, which is the most frequent pathway, until", "section": "SUL", "page_from": 3, "page_to": 3, "display_name": "EANM", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "7dd7577d7c1a8f215ef67fa01ba8bcaa677be7278d806b6411d46b9cb07e08cc"}
{"doc_id": "eanm__v00000000", "chunk_id": "000014", "text": "•\t Lymphatic dissemination may circulate through three\nalternative pathways: (a) following the ovarian lym-\nphatic vessels, which is the most frequent pathway, until\nit arrives at the upper common iliac and paraaortic lymph\nnodes; (b) following the broad ligament and parame-\ntrium, until it arrives at the external iliac and obturator\nlymph nodes; and (c) very scarcely, following the round\nligaments, in the direction of the external iliac and ingui-\nnal lymph nodes [11–14].\n•\t Haematogenous dissemination is not as frequent, target-\ning the liver, lung, spleen, central nervous system and, in\nfew cases, bone [13].\nOver 66% of cases are detected when the disease is\nalready advanced due to malignant cells having already\nreached extrapelvic structures, such as FIGO stages III and\nIV. The late diagnosis is caused, on one hand, by the typi-\ncally vague presenting symptoms and, on the other hand, the\nlack of an effective screening program.\nStaging systems of ovarian cancer: FIGO\nand AJCC‑TNM\nAt present, the most frequent worldwide staging system\nadopted for this primary tumour is the FIGO classification\n3288\nEuropean Journal of Nuclear Medicine and Molecular Imaging  (2021) 48:3286–3302", "section": "SUL", "page_from": 3, "page_to": 3, "display_name": "EANM", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "60997671062823e36e3dbbad172927d7233b32bf9d2c488ab0dd38f9290d6a1f"}
{"doc_id": "eanm__v00000000", "chunk_id": "000015", "text": "At present, the most frequent worldwide staging system\nadopted for this primary tumour is the FIGO classification\n3288\nEuropean Journal of Nuclear Medicine and Molecular Imaging  (2021) 48:3286–3302\n1 3", "section": "SUL", "page_from": 3, "page_to": 3, "display_name": "EANM", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "85b418b9729440ccd1ba544b02e1c8e311feb16d3a01e9b4876624f7d11c490b"}
{"doc_id": "eanm__v00000000", "chunk_id": "000016", "text": "[15, 16]. Initially established in 1973, the last revision dates\nback to 2014. It defines the features, extent and prognosis of\nthe tumour, in order to achieve the best possible outcome fol-\nlowing an optimized and personalized therapeutic approach.\nThe comparison between the American Joint Committee on\nCancer (AJCC) tumour–node–metastasis (TNM) and FIGO\nstaging systems is presented in Table 1 [8, 15–17].\nIt is frequently discussed in the literature the heterogene-\nity of ovarian cancer, overarching different diseases that have\ndissimilar aetiology, pathogenesis, pathology and prognosis\nand that can initially appear affecting the ovaries, the fal-\nlopian tubes or the peritoneum. FIGO’s 2014 classification\nincludes as a single diagnostic category the tumours affect-\ning ovaries, fallopian tube and primary peritoneal tumours.\nLaboratory\nAfter a complete anamnesis and physical exploration, serum\nCA-125 is commonly studied in the initial evaluation [7].\nIn early disease (FIGO stage I), its utility is controversial\nbecause it is increased only in around half of the patients. In\nadvanced disease (FIGO stage II or greater), CA-125 pre-", "section": "The comparison between the American Joint Committee on", "page_from": 4, "page_to": 4, "display_name": "EANM", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "ce67483a87fd7f356017e38a131cb020de5631cad256bb075ed7d1f9cb99fbcb"}
{"doc_id": "eanm__v00000000", "chunk_id": "000017", "text": "In early disease (FIGO stage I), its utility is controversial\nbecause it is increased only in around half of the patients. In\nadvanced disease (FIGO stage II or greater), CA-125 pre-\nsents increased values in around 85% of cases. However,\nan important issue is the lack of specificity as CA-125 is\nincreased in non-ovarian malignancies (e.g. breast, lung,\ncolon and pancreatic tumours), pregnancy and benign dis-\neases (e.g. cirrhosis, endometriosis, pelvic inflammatory dis-\nease and ovarian cysts). Serum carcinoembryonic antigen\n(CEA) and CA 19–9 values occasionally may help in clari-\nfying the origin of the ovarian tumour, whether if the origin\nis gastrointestinal or a primary mucinous ovarian cancer.\nIn this regard, endoscopic procedures, such as colonoscopy\nand/or gastroscopy, may be useful, especially if CA-125/\nCEA ratio is ≤ 25 [18], although this is controversial. On the\nother hand, CA-125 is considered a good marker of tumour\nrecurrence. The correlation between CA-125 levels and the\nclinical evolution during chemotherapy is very strong. In\nclinically tumour-free patients, CA-125 values have a prog-\nnostic value and can be useful for predicting relapse [19].", "section": "The comparison between the American Joint Committee on", "page_from": 4, "page_to": 4, "display_name": "EANM", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "e1549535860e2caabf42541545ae684260aa1cee246d3272973d5c18f5a0fb35"}
{"doc_id": "eanm__v00000000", "chunk_id": "000018", "text": "clinical evolution during chemotherapy is very strong. In\nclinically tumour-free patients, CA-125 values have a prog-\nnostic value and can be useful for predicting relapse [19].\nRadiological imaging in ovarian cancer\nRandomized clinical trials did not show benefits from\nscreening procedures in ovarian cancer. The only settings\nwhere they may be appropriate are high-risk patients both\npre- and postmenopausal and especially BRCA-mutated\npatients. Transvaginal and transabdominal ultrasound are\nthe imaging procedures of choice [19].\nStudying ovarian or adnexal masses with the medical\nimaging methods (ultrasound, US; computed tomography,\nCT; and magnetic resonance imaging, MRI) is frequent\nin post- and premenopausal women [20]. Ovarian masses\ncan be either benign or malignant, although they are more\nfrequently benign lesions, such as endometriomas (deep\novarian endometriosis), or corpus luteum cysts (both mainly\npremenopausal), thecomas, dermoid cysts and serous cys-\ntadenomas. Therefore, the impact on the subsequent man-\nagement decisions of these imaging findings defining the\nmalignancy or not of these masses is very high.\nTransvaginal US (TVUS) combined with power Doppler", "section": "The comparison between the American Joint Committee on", "page_from": 4, "page_to": 4, "display_name": "EANM", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "d5dae52df0ab898433907c91cb168d113be80ac2b8be69191687dfb535df2055"}
{"doc_id": "eanm__v00000000", "chunk_id": "000019", "text": "agement decisions of these imaging findings defining the\nmalignancy or not of these masses is very high.\nTransvaginal US (TVUS) combined with power Doppler\nis the initial imaging test (sometimes in combination with\ntransabdominal US, TAUS). There is consensus that it is\nthe imaging procedure of choice in patients with adnexal\nmasses for studying the original location and its benign or\nmalignant features. Characteristics of the masses that are\nconsidered as suspicious of malignancy are thick irregular\nwalls or with papillary projections and solid echogenic foci,\nmoreover if appearing associated with ascites or peritoneal\nnodules [21–24]. In this regard, power Doppler tests may\nadd information to detect tumour neovascularity within solid\nmasses [24].\nThe International Ovarian Tumour Analysis group\n(IOTA) has addressed the absence of uniform and standard\nguidelines in gynaecological ultrasonography as the limiting\nfactor in the early diagnosis. The IOTA rules have introduced\na standardized examination technique to define morphologi-\ncal features of ovarian masses. The IOTA simple ultrasound\nrules categorize ovarian tumours as benign or malignant and", "section": "The comparison between the American Joint Committee on", "page_from": 4, "page_to": 4, "display_name": "EANM", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "c39125ff7e9ceec12c03b3b69b1eff25c179186a225a7c252891424a5921d794"}
{"doc_id": "eanm__v00000000", "chunk_id": "000020", "text": "a standardized examination technique to define morphologi-\ncal features of ovarian masses. The IOTA simple ultrasound\nrules categorize ovarian tumours as benign or malignant and\nestablish their application for the early detection of ovarian\ncancer. The IOTA published both simple rules and complex\nmathematical models based on logistic regression, allowing\nreproducible studies, simple to train and apply clinically for\nestimating the risk of malignancy [25].\nHowever, up to one-fifth (5–20%) of these lesions are\nclassified as indeterminate with ultrasonography. Here, MRI\ncan provide an added value with complementary information\n[26]. Also, contrast-enhanced CT (ceCT) can be helpful as\nit can evidence solid enhancing components within adnexal\nmasses and detect peritoneal tumour spread [19].\nRegarding MRI, taking into account its main features\nwhen analysing T1- and T2-weighted images, indeterminate\nadnexal masses may be classified in three groups: (a) T1\nhighly intense masses, (b) solid masses with high or inter-\nmediate T2 signal and (c) complex cystic or cystic-solid\nmasses. The first group, based on the loss or absence of\nsignal in fat-suppressed T1-weighted imaging, can lead to", "section": "The comparison between the American Joint Committee on", "page_from": 4, "page_to": 4, "display_name": "EANM", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "b5fa794bfeb20a10637fa49113f0aa4b682d3990cd087c5ca4867bcc380d9d95"}
{"doc_id": "eanm__v00000000", "chunk_id": "000021", "text": "mediate T2 signal and (c) complex cystic or cystic-solid\nmasses. The first group, based on the loss or absence of\nsignal in fat-suppressed T1-weighted imaging, can lead to\nmature teratoma and haemorrhagic masses, respectively. In\nthe second group, based on the relationship or not with the\nuterus, a distinction can be done between uterine leiomyoma\nand ovarian fibroma, while the gadolinium enhancement can\nbe useful for characterizing solid masses with inhomoge-\nneous low or intermediate T2 signal. Lastly, in the third\ngroup and, anyway, in cases of solid components inside the\nmass, gadolinium enhancement T1-weighted sequences are\nrequired in order to establish or refute tumour enhancement\n3289\nEuropean Journal of Nuclear Medicine and Molecular Imaging  (2021) 48:3286–3302\n123456789)\n1 3", "section": "The comparison between the American Joint Committee on", "page_from": 4, "page_to": 4, "display_name": "EANM", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "b931e744702e537fc61091876495598cadedd7bceb5e65a51f4ca6d58fe873da"}
{"doc_id": "eanm__v00000000", "chunk_id": "000022", "text": "[13, 26, 27]. Other MRI sequences may also be useful for\nthe characterization of these masses [26, 27].\nCT from the thoracic apex to the pelvis is considered the\npreferred imaging procedure for presurgical evaluation and\nstaging. There are publications focusing on which are the\ncrucial imaging findings and diagnostic criteria as well as\nfor generating a structured report for preoperative staging\n[13, 28].\nTable 1   Comparison between AJCC and FIGO staging systems\nAJCC stage FIGO stage Stage grouping\nStage description\nI\nI\nT1\nThe cancer is in the ovaries or fallopian tubes without any other spread\nN0\nM0\nIA\nIA\nT1a\nLesion localized inside to one ovary or to one fallopian tube without cancer cells in the fluid or\nwashings from the abdomen and pelvis\nN0\nM0\nIB\nIB\nT1b\nLesions localized inside both ovaries or fallopian tubes without cancer cells in the fluid or washings\nfrom the abdomen and pelvis\nN0\nM0\nIC\nIC\nLesion in one or both ovaries or fallopian tubes with:\nT1c\nT1c1 Broken capsule during surgery\nT1c2 Lesion in the surface of at least one organ or broken capsule before surgery\nT1c3 Cancer cells in the fluid or washings from the abdomen and pelvis\nN0\nM0\nII\nII\nT2", "section": "CT from the thoracic apex to the pelvis is considered the", "page_from": 5, "page_to": 5, "display_name": "EANM", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "d114a7fdddd1e1040eed6962ab46a87857c2564c7f59e4fe12429883fb1ab8cd"}
{"doc_id": "eanm__v00000000", "chunk_id": "000023", "text": "T1c2 Lesion in the surface of at least one organ or broken capsule before surgery\nT1c3 Cancer cells in the fluid or washings from the abdomen and pelvis\nN0\nM0\nII\nII\nT2\nLesion in one or both ovaries/fallopian tubes with spread to other pelvic organs or primary perito-\nneal cancer\nN0\nM0\nIIA\nIIA\nT2a\nTumoural extension to the uterus or the fallopian tubes\nN0\nM0\nIIB\nIIB\nT2b\nTumoural extension to the bladder, sigmoid colon or rectum\nN0\nM0\nIIIA1\nIIIA1\nT1 or T2\nTumoural extension as described\nN1\nSpread to the retroperitoneal (pelvic and/or paraaortic) lymph nodes\nM0\nIIIA2\nIIIA2\nT3a\nTumoural extension as described with microscopic extrapelvic peritoneal deposits\nN0 or N1\nSpread or not to retroperitoneal lymph nodes\nM0\nIIIB\nIIIB\nT3b\nTumoural extension as described with macroscopic (< 2 cm) extrapelvic peritoneal deposits\nN0 or N1\nSpread or not to retroperitoneal lymph nodes\nM0\nIIIC\nIIIC\nT3c\nTumoural extension as described with macroscopic (> 2 cm) extrapelvic peritoneal deposits\nN0 or N1\nSpread or not to retroperitoneal lymph nodes\nM0\nIVA\nIVA\nAny T\nPleural effusion with confirmed metastatic cells\nAny N\nM1a\nIVB\nIVB\nAny T", "section": "CT from the thoracic apex to the pelvis is considered the", "page_from": 5, "page_to": 5, "display_name": "EANM", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "3138023ab090dcd6672447ecbdfe36c2825538d7de330b020649c75363d6a08e"}
{"doc_id": "eanm__v00000000", "chunk_id": "000024", "text": "N0 or N1\nSpread or not to retroperitoneal lymph nodes\nM0\nIVA\nIVA\nAny T\nPleural effusion with confirmed metastatic cells\nAny N\nM1a\nIVB\nIVB\nAny T\nSpread in extraperitoneal organs or inside the spleen or liver, as well as to lymph nodes different\nfrom retroperitoneal lymph nodes\nAny N\nM1b\n3290\nEuropean Journal of Nuclear Medicine and Molecular Imaging  (2021) 48:3286–3302\n1 3", "section": "CT from the thoracic apex to the pelvis is considered the", "page_from": 5, "page_to": 5, "display_name": "EANM", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "f08d0b3ecf9304bce3a5d123b6077932bcc85cc55fbf348c9047e6d9da348ed9"}
{"doc_id": "eanm__v00000000", "chunk_id": "000025", "text": "Treatment\nCytoreductive (also called debulking) surgical procedures\nand chemotherapy (platinum-based) are the cornerstones of\novarian cancer therapeutical management.\nCytoreductive surgery\nPrimary cytoreductive surgery is aimed to remove com-\npletely the tumour before subsequent chemotherapy is\nadministered, while interval cytoreductive surgery is done\nfollowing neoadjuvant chemotherapy, usually three cycles.\nComplete cytoreduction, or R0, is defined as the result\nof a surgical procedure that has cleared all macroscopic\ntumour, leaving no macroscopic residual disease. There is\nevidence that complete cytoreduction is the best independent\nprognostic factor in advanced ovarian cancer. Thus, a pre-\ncise presurgical staging is key for defining the management\nplan. If complete cytoreduction is feasible with an accept-\nable surgical morbidity, primary debulking surgery should\nbe offered [29–31].\nAccording to the European Society for Medical Oncol-\nogy (ESMO)-European Society of Gynaecological Oncol-\nogy (ESGO) recommendations [29, 30], a multidisciplinary\nteam working in a centre specialized in ovarian cancer must\nbe in charge of patient selection for either primary debulking", "section": "Treatment", "page_from": 6, "page_to": 6, "display_name": "EANM", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "b614d0b6ef9f82ac30beec6eef134f2b35dc2f9b59257c6bda1becd26796be13"}
{"doc_id": "eanm__v00000000", "chunk_id": "000026", "text": "ogy (ESGO) recommendations [29, 30], a multidisciplinary\nteam working in a centre specialized in ovarian cancer must\nbe in charge of patient selection for either primary debulking\nsurgery or neoadjuvant chemotherapy. Radiological imaging\nor diagnostic laparoscopy must be part of the standard diag-\nnostic and staging algorithm. Exclusion criteria from pri-\nmary surgery, based on ESGO guidelines on ovarian cancer\nsurgery [31], when the tumour has spread with the following\nfindings, among other factors, in the diagnostic work-up are\nextensive and profound invasion of the root of small intes-\ntine mesentery; diffuse carcinomatosis of the small intestine\nwith such an extensive dissemination that surgical clearance\nwould produce a short bowel syndrome (the intestine left\nmeasuring less than 1.5 m); gastric/duodenal, head or mid-\ndle part of the pancreas diffuse disease/profound invasion;\ntumour affecting coeliac trunk, hepatic arteries, left gastric\nartery; central or multisegmental hepatic secondary lesions;\nmultiple lung secondary lesions (preferably pathologically\nconfirmed); non-resectable lymphadenopathies; and central\nnervous system secondary lesions.\nNodal staging", "section": "Treatment", "page_from": 6, "page_to": 6, "display_name": "EANM", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "19d22f70d13d974df8cfabecf6042b53a925766465ec90c5cf32d73ddd14231a"}
{"doc_id": "eanm__v00000000", "chunk_id": "000027", "text": "multiple lung secondary lesions (preferably pathologically\nconfirmed); non-resectable lymphadenopathies; and central\nnervous system secondary lesions.\nNodal staging\nWith regard to nodal staging, there has been a paradigm\nchange in the last few years. In early-stage ovarian carcinoma\n(EOC), ESMO-ESGO guidelines indicate that the required\nmanagement includes nodal staging surgery. In presurgical\nstage I patients, this surgical procedure must encompass a\nbilateral pelvic and paraaortic lymphadenectomy up to the\nleft renal vein (independently of the surgical approach). In\nany case, given the low prevalence of lymphatic infiltration\nin certain pathology subtypes (e.g. mucinous carcinoma of\nexpansile subtype or low-grade serous carcinoma, LGSC),\nthere are doubts and discussion regarding the indication for\nstaging surgery in these patients (ESMO-ESGO recommen-\ndation, level of evidence, IV; strength of the recommenda-\ntion, A) [29, 30]. When referring to lymph node dissection\nwith the aim of restaging, the procedure can be eluded when\nnodal status will not change clinical or therapeutic deci-\nsions (ESMO-ESGO recommendation, level of evidence, V;", "section": "Treatment", "page_from": 6, "page_to": 6, "display_name": "EANM", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "15cb6bdf88053107c3eaae50e0b6a0ed83630b4dfd9f226af9a833e3a87a9f9b"}
{"doc_id": "eanm__v00000000", "chunk_id": "000028", "text": "with the aim of restaging, the procedure can be eluded when\nnodal status will not change clinical or therapeutic deci-\nsions (ESMO-ESGO recommendation, level of evidence, V;\nstrength of the recommendation, B) [29, 30]. In the case of\nserous borderline ovarian tumours (sBOTs) with peritoneal\nimplants, there is evidence that residual disease has a prog-\nnostic value. In this situation, both from a staging point of\nview and a therapeutical objective, it is of utmost importance\nto aim at an entire removal of peritoneal implants. In the\ncase of stage II/III sBOTs, there is no evidence of improved\nevolution following lymphadenectomy (level of evidence,\nIV; strength of the recommendation, B) [29, 30]. Finally,\nregarding the cases with advanced ovarian cancer (AOC), the\nrecently published lymphadenectomy in ovarian neoplasms\n(LION) trial [32] provided evidence on the limitations of\nlymphadenectomy. Available first-level evidence, coming\nfrom randomized clinical trials, is limited regarding the util-\nity of systematic pelvic and paraaortic lymphadenectomy that\nhas, however, been broadly applied in the surgical treatment\nof patients with advanced ovarian cancer. The LION trial", "section": "Treatment", "page_from": 6, "page_to": 6, "display_name": "EANM", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "9fb6dbbcc9e300156196289eb2cd5e61fe97a4a582a943cfefdbc595dfcac21e"}
{"doc_id": "eanm__v00000000", "chunk_id": "000029", "text": "ity of systematic pelvic and paraaortic lymphadenectomy that\nhas, however, been broadly applied in the surgical treatment\nof patients with advanced ovarian cancer. The LION trial\ndemonstrated that, in advanced ovarian cancer cases with\nintraabdominal macroscopically complete resection and nor-\nmal lymph nodes both before and during surgery, system-\natic pelvic and paraaortic lymphadenectomy in cases with\nadvanced ovarian cancer was not associated with improved\nsurvival (overall or progression-free) compared to no lym-\nphadenectomy but was associated with more postsurgical\ncomplications [32].\nSystemic treatment\nThe first-line ovarian cancer treatment and standard-of-\ncare chemotherapy is the carboplatin/paclitaxel combina-\ntion. Bevacizumab and poly(adenosine diphosphate-ribose)\npolymerase (PARP) inhibitors are now incorporated in the\nmanagement guidelines. In addition to standard chemo-\ntherapy, some patients may be treated with molecularly\ntargeted therapies. The addition of bevacizumab, an antian-\ngiogenic drug, should be considered in patients with stage\nIII–IV ovarian cancer. The use of maintenance therapy with\nolaparib, an oral PARP inhibitor, demonstrated significant", "section": "Treatment", "page_from": 6, "page_to": 6, "display_name": "EANM", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "91331fbd1787deee0ddebfadf90b9feeef29c9e5705972bea637e4247a05ca16"}
{"doc_id": "eanm__v00000000", "chunk_id": "000030", "text": "giogenic drug, should be considered in patients with stage\nIII–IV ovarian cancer. The use of maintenance therapy with\nolaparib, an oral PARP inhibitor, demonstrated significant\nadvantages regarding progression-free survival especially\nin patients with initially diagnosed advanced ovarian cancer\nwith BRCA1/2 mutation, as shown in the SOLO1 trial [29,\n30, 33].\n3291\nEuropean Journal of Nuclear Medicine and Molecular Imaging  (2021) 48:3286–3302\n123456789)\n1 3", "section": "Treatment", "page_from": 6, "page_to": 6, "display_name": "EANM", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "bdb77a286b34a003150f59ae3f2312f2d9ff60e3b4832631d3838652f5ce1efd"}
{"doc_id": "eanm__v00000000", "chunk_id": "000031", "text": "Around 70% of cases will recur in the first 3 years. In\nthese patients, the progression-free interval after finishing\nthe preceding line of chemotherapy is strongly associated\nwith the prognosis and probability of response to second-\nline chemotherapy and subsequent chemotherapy lines.\nTraditionally, patients that present disease progression\nin the first 6 months after finishing platinum-based chemo-\ntherapy are considered to be platinum-resistant and are\nunlikely to benefit from a re-challenge by platinum-based\nchemotherapy, while patients presenting progressive dis-\nease in the time interval of more than 6 or even 12 months\nare considered platinum-sensitive and likely to respond to\nplatinum therapy. This concept, developed when alternatives\nto platinum re-treatment were scarce, presents limitations\nand was discontinued at the fifth Ovarian Cancer Consensus\nConference of the Gynecologic Cancer InterGroup (GCIG)\n[34]. Bevacizumab could be recommended both combined\nwith platinum-based therapy and, after, as maintenance ther-\napy in those cases presenting a platinum-free interval (PFI)\nover 6 months and in combination with second- or third-", "section": "Treatment", "page_from": 7, "page_to": 7, "display_name": "EANM", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "b957d4b4d738520381285514a7f05255883a66893908d7481209576cfb0a923a"}
{"doc_id": "eanm__v00000000", "chunk_id": "000032", "text": "with platinum-based therapy and, after, as maintenance ther-\napy in those cases presenting a platinum-free interval (PFI)\nover 6 months and in combination with second- or third-\nline non-platinum chemotherapy (weekly paclitaxel, PLD,\ntopotecan) in patients with shorter PFI. PARP inhibitors\n(olaparib, niraparib and rucaparib) could be recommended\nas maintenance therapy after a response to platinum-based\nsecond or higher line of treatment. Their benefit is highest in\npatients presenting BRCA mutation, although those without\nBRCA mutation also benefit of the therapy. Furthermore, in\nselected cases presenting a first relapse, complete cytore-\nductive surgery followed by chemotherapy achieves better\nprogression-free survival (PFS) and makes the beneficial\neffect extensive to the next chemotherapy line [29, 30].\nIn the era of precision medicine, research focuses on\nlooking for targeted therapies for the different histological\nsubtypes with their specific molecular features and different\nchemosensitivity and also variable CA-125 expression and\npositron emission tomography (PET) imaging semiology\nwith dedicated radiopharmaceuticals. The targeted treat-", "section": "Treatment", "page_from": 7, "page_to": 7, "display_name": "EANM", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "6610b67e5b1bc1f2aafc5a0e991c011bd61c09a4a40e11bb2813740ba1116910"}
{"doc_id": "eanm__v00000000", "chunk_id": "000033", "text": "chemosensitivity and also variable CA-125 expression and\npositron emission tomography (PET) imaging semiology\nwith dedicated radiopharmaceuticals. The targeted treat-\nments being investigated are immune checkpoint inhibitors,\nPARP inhibitors, hormone receptor modulators and antian-\ngiogenic agents [29, 30].\nFollow‑up\nClinical evaluation and CA-125 are the standard in the fol-\nlow-up of ovarian cancer after primary treatment [28]. The\nindications and application of imaging procedures (ultra-\nsound, chest–abdomen–pelvis CT, whole-body MRI or PET/\nCT) have to be based on sound clinical indications, deriving\neither from symptoms, signs or increasing CA-125 values\n[29, 30]. In patients in which there is suspicion of relapse,\nCT is the preferred technique, although PET/CT can be a\nvalid alternative if performed with contrast enhancement, as\nthe contrast-enhanced CT component is mandatory in this\nsetting to accurately evaluate peritoneal carcinomatosis.\nPET/CT procedure\n2‑[18F]FDG PET/CT acquisition\nThe 2-[18F]FDG PET/CT procedure has been described in\nthe EANM guideline [35]. In ovarian cancer it is important\nto effectively search for cancer deposits in the regions where", "section": "Treatment", "page_from": 7, "page_to": 7, "display_name": "EANM", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "cbcf27752b2bc4811d7123f7405f5bd1c6b6752a7aba506942c61f5901cc89fc"}
{"doc_id": "eanm__v00000000", "chunk_id": "000034", "text": "The 2-[18F]FDG PET/CT procedure has been described in\nthe EANM guideline [35]. In ovarian cancer it is important\nto effectively search for cancer deposits in the regions where\nthis tumour spreads more frequently, namely, the perito-\nneum, the lymphatic system and the bloodstream.\nIf ceCT can be done as part of the 2-[18F]FDG PET/CT,\nit may be evaluated by the multidisciplinary tumour board\nto avoid performing an additional separate diagnostic CT.\nIt is generally considered helpful to obtain multiphase\ncontrast-enhanced CT imaging in patients with known/sus-\npected ovarian cancer, especially for the evaluation of the\nliver, lymph nodes, mesentery, omentum, pleura and lungs.\nAll available patient CT dose reduction methods should be\nconsidered, including automatic exposure control and itera-\ntive reconstruction.\nData extraction and analysis\nQualitative PET/CT categorizes the findings into malignant,\nindeterminate or benignant. 2-[18F]FDG uptake is visually\ncompared with the background and with other structures,\nsuch as the mediastinum and the liver. Based on the degree\nof 2-[18F]FDG uptake and the particular context of the study", "section": "Treatment", "page_from": 7, "page_to": 7, "display_name": "EANM", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "17f228434ddafbfcc7cf30c2b66d85ce90bf01f8eda994218159be1bcfccd863"}
{"doc_id": "eanm__v00000000", "chunk_id": "000035", "text": "compared with the background and with other structures,\nsuch as the mediastinum and the liver. Based on the degree\nof 2-[18F]FDG uptake and the particular context of the study\n(clinical indication, previous treatments and concomitant\nprocesses), the findings are categorized into the aforemen-\ntioned qualitative values.\nQuantitative PET/CT may be applied as a diagnostic or\nprognostic tool (i.e. single measurement) or for therapy\nresponse assessment (i.e. longitudinal studies). Metrics\ninclude standardized uptake values (SUV, general acro-\nnym) computed either using the body weight (SUV) or the\nlean body mass (SUL), metabolic active tumour volume\n(MATV or MTV) and total lesion glycolysis (TLG), defined\nas MATV × SUVmean. In fact, MATV is the volume inside a\nuser- or algorithm-defined volume of interest (VOI) used to\ncircumscribe the metabolically active tumour. Several tech-\nniques have been proposed to determine the limits of the\nVOI, threshold-based or algorithm-based [36], while TLG\ncalculated by multiplying MATV by the mean SUV of all\nvoxels in the MATV incorporates both 2-[18F]FDG uptake\nand size of the tumour, also known as whole metabolic bur-\nden of the tumour [37].", "section": "Treatment", "page_from": 7, "page_to": 7, "display_name": "EANM", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "2e7c06f7f8c8880bc83b980dfea7bbdc573ff5fae70d6e480eed1465a7871abb"}
{"doc_id": "eanm__v00000000", "chunk_id": "000036", "text": "calculated by multiplying MATV by the mean SUV of all\nvoxels in the MATV incorporates both 2-[18F]FDG uptake\nand size of the tumour, also known as whole metabolic bur-\nden of the tumour [37].\nThe use of quantitative 2-[18F]FDG PET/CT parameters\nas imaging biomarkers in centres that have several PET/\nCT systems or in trials involving different PET/CT systems\n3292\nEuropean Journal of Nuclear Medicine and Molecular Imaging  (2021) 48:3286–3302\n1 3", "section": "Treatment", "page_from": 7, "page_to": 7, "display_name": "EANM", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "a53564bed0e21a171c2bec1a5929991602c193d53f7c4bad324f34323538d1fe"}
{"doc_id": "eanm__v00000000", "chunk_id": "000037", "text": "requires a minimum standardization to make these parame-\nters comparable between patients, independently of the PET/\nCT scanner acquiring the images.\nDelineation of MATVs may be affected by similar errors\nas occur when calculating SUVs, leading to one of the main\ncauses of variability, which is variations in the delineation\nmethodology of lesions [38]. MATVs also allow extraction\nof heterogeneity features. However, radiomic features are\ngreatly affected and sensitive to a few confounding factors,\nbeing image reconstruction settings an example, and this\ntranslates into challenges when aiming at its clinical imple-\nmentation [39, 40].\nIt is therefore recommended to comply with harmoniz-\ning standards such as the EANM/EARL program, one of\nthe international harmonization programs aiming at using\n2-[18F]FDG PET/CT as a quantitative imaging biomarker\n[41]. Radiomics should also follow the definitions of the\nimage biomarker standardization initiative (IBSI).\nIn addition to harmonization issues, attention should be\npaid to avoid including ureters or bladder when computing\nMATV in patients with bulky disease (Fig. 1).\nTherapy assessment should be performed according to", "section": "Delineation of MATVs may be affected by similar errors", "page_from": 8, "page_to": 8, "display_name": "EANM", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "90c3dc20bd6c77a4425dfd8380b23fdde2e41329a3f4d3e2077408e270ddde08"}
{"doc_id": "eanm__v00000000", "chunk_id": "000038", "text": "paid to avoid including ureters or bladder when computing\nMATV in patients with bulky disease (Fig. 1).\nTherapy assessment should be performed according to\neither the European Organisation for Research and Treat-\nment of Cancer (EORTC) PET response criteria or PER-\nCIST [42–44]. In addition to the use of the area harbouring\nthe highest uptake, it is recommended to explore peritoneal\nindex-adapted PERCIST classification where the 5 target\nlesions would be based on one of the scores that have been\ndeveloped for assessing the extension of peritoneal carci-\nnomatosis. Several scores for laparotomic assessment of\ntumour/carcinomatosis extension have been described: the\nSugarbaker score or the peritoneal cancer index (PCI) and\nthe Aletti, Fagotti and Eisenkop scores, which attribute a\nscore to several anatomical regions of the abdomen [45, 46].\n2‑[18F]FDG PET/CT indications\n•\t Initial diagnosis and staging\n•\t Prognostic value\n•\t Treatment planning\n–\t Evaluation of tumour resectability\n–\t Predictive value before upfront debulking surgery or\ninterval debulking surgery\n–\t Predictive value before chemotherapy\n•\t Therapy assessment\n–\t Chemotherapy\n•\t Relapse detection", "section": "Delineation of MATVs may be affected by similar errors", "page_from": 8, "page_to": 8, "display_name": "EANM", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "7efb7872e2f9c70dfeb52c409dab3608e9b2fccbece10ede3c86ad8e3f635167"}
{"doc_id": "eanm__v00000000", "chunk_id": "000039", "text": "–\t Predictive value before upfront debulking surgery or\ninterval debulking surgery\n–\t Predictive value before chemotherapy\n•\t Therapy assessment\n–\t Chemotherapy\n•\t Relapse detection\n–\t Non-conclusive radiological imaging\n–\t Negative radiological imaging with increased tumour\nmarkers\n•\t Follow-up\nFig. 1   Example of metabolic\nactive tumour volume (MATV)\ndelineation in a patient with\nstage IIIc FIGO ovarian cancer\nenrolled in the CHIVA trial\n[95] in the chemotherapy plus\nplacebo arm. Attention should\nbe paid to avoid including the\nureters or bladder in the tumour\nburden when drawing MATV.\nEarly therapy assessment\n2-[18F]FDG PET/CT (b) was\nperformed 20 days after base-\nline scan (a), after the first cycle\nof treatment. This patient was\nclassified as stable metabolic\ndisease as per PERCIST therapy\nresponse criteria. Maximum\nintensity projections (MIP) of\n2-[18F]FDG PET are presented\n3293\nEuropean Journal of Nuclear Medicine and Molecular Imaging  (2021) 48:3286–3302\n123456789)\n1 3", "section": "Delineation of MATVs may be affected by similar errors", "page_from": 8, "page_to": 8, "display_name": "EANM", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "9fdad6ec4cd467c273921904d1ad777793451c94451da4488330df19c165262d"}
{"doc_id": "eanm__v00000000", "chunk_id": "000040", "text": "Each indication has been reviewed, assigning a level of\nevidence and a recommendation grade (Table 2) following\nthe National Institute for Health and Clinical Excellence\n(NICE) adaptation, as previously used [47, 48], as follows:\nLevels of evidence\nThe level of evidence is a rating of the literature data on\nwhich the recommendations formulated are based. The level\ndepends on the type and quality of studies available and\ndegree of consistency across their results. Details of the lev-\nels of evidence used are presented below:\n•\t Level I: There are good-quality meta-analyses or good-\nquality randomized trials with cross-consistent results.\nNew data will most likely not change confidence in the\nestimated effect.\n•\t Level II: There is good-quality evidence (randomized tri-\nals (B1) or prospective or retrospective studies (B2) with\noverall cross-consistent results. New data may impact\nconfidence in the estimate of effect or may change the\nestimate.\n•\t Level III: The studies available carry methodological\nweaknesses, and/or the results of the studies are not\nalways cross-consistent. New data will most likely impact\nconfidence in the estimate of effect and will likely change\nthe estimate.", "section": "Delineation of MATVs may be affected by similar errors", "page_from": 9, "page_to": 9, "display_name": "EANM", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "46e4546a6fecd3187be3d7f5c9d210c3bb57102df096611f076cf1414459640e"}
{"doc_id": "eanm__v00000000", "chunk_id": "000041", "text": "weaknesses, and/or the results of the studies are not\nalways cross-consistent. New data will most likely impact\nconfidence in the estimate of effect and will likely change\nthe estimate.\n•\t Level IV: There are no data or only case series. There is\na great deal of uncertainty as to the estimated effect.\nGrades of recommendation\n•\t A: At least one meta-analysis, systematic review or rand-\nomized controlled trials (RCT) directly applicable to the\ntarget population and demonstrating overall consistency\nof results\n•\t B: A body of evidence including high-quality systematic\nreviews of case–control or cohort studies, directly appli-\ncable to the target population, and demonstrating overall\nconsistency of results\n•\t C: A body of evidence including well-conducted case–\ncontrol or cohort studies with a low risk of confounding\nor bias, directly applicable to the target population and\ndemonstrating overall consistency of results\n•\t D: Non-analytic studies, e.g. case reports, case series and\nexpert opinion\nInitial diagnosis and staging in patients presenting\nwith a pelvic mass\nLevel of evidence: III\nRecommendation: grade C\nMany publications have focused on the diagnostic effi-", "section": "Delineation of MATVs may be affected by similar errors", "page_from": 9, "page_to": 9, "display_name": "EANM", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "bc468d1fefe6fef296dbf917079cdb3b099d439e59f990fc16fd797ef2becbf9"}
{"doc_id": "eanm__v00000000", "chunk_id": "000042", "text": "expert opinion\nInitial diagnosis and staging in patients presenting\nwith a pelvic mass\nLevel of evidence: III\nRecommendation: grade C\nMany publications have focused on the diagnostic effi-\ncacy of 2-[18F]FDG PET/CT for ovarian cancer in patients\npresenting with a pelvic mass, aiming at ameliorating man-\nagement decisions identifying patients in whom surgical\nintervention is indicated (positive PET). With the aim of\ndetecting ovarian tumours in fifty consecutive patients pre-\nsenting a pelvic mass and had a surgical intervention sched-\nuled, Castellucci et al. [49] reported comparable sensitivity\nfor 2-[18F]FDG PET/CT and TVUS (around 87–90%), but\n2-[18F]FDG PET/CT presented better specificity. In another\nprospective study of 97 patients presenting pelvic masses,\nRisum et al. reported high specificity of 2-[18F]FDG PET/\nCT for detecting malignant disease related to ovarian cancer\nas well as high sensitivity (92.5% and 100%, respectively)\n[50]. Nam et al. [51] in 133 women obtained 2-[18F]FDG\nPET/CT accuracy (92%), better than pelvic power Doppler\nUS (83%) and CT/MR (74%) in differentiating benign vs\nborderline/malignant adnexal masses.", "section": "Delineation of MATVs may be affected by similar errors", "page_from": 9, "page_to": 9, "display_name": "EANM", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "873ee1ebe2871d1d9ffd89584eeb16272d2bf4f17f326ac9908a76527143685a"}
{"doc_id": "eanm__v00000000", "chunk_id": "000043", "text": "PET/CT accuracy (92%), better than pelvic power Doppler\nUS (83%) and CT/MR (74%) in differentiating benign vs\nborderline/malignant adnexal masses.\nThe pathophysiologic bases of the aforementioned\nobservations include glucose transporter 1 (GLUT-1) over-\nexpression and microvessel density/tumour proliferation,\nboth being indicators of tumour aggressiveness and worse\nprognosis. Therefore, researchers indicate that 2-[18F]FDG\nPET/CT helps ameliorate patient selection for surgery and\nas guidance for cytoreductive surgery [52, 53]. Moreover,\nstaging with 2-[18F]FDG PET/CT coincided with surgical\nstaging in 78% of cases, indicating 2-[18F]FDG PET/CT may\nbe applied in the presurgical staging of patients in which\novarian cancer is suspected [51]. Thus, even if Yamamoto\net al. and Kitajima et al. [54, 55] confirmed high 2-[18F]\nFDG PET/CT sensitivity and specificity in differentiating\nmalignant from benign ovarian masses, their reports present\nlow diagnostic efficacy when discriminating between bor-\nderline–malignant and benign lesions. Furthermore, even\nafter positive findings when analysing the diagnostic value\nof 2-[18F]FDG PET/CT in ovarian cancer, Fenchel et al.", "section": "Delineation of MATVs may be affected by similar errors", "page_from": 9, "page_to": 9, "display_name": "EANM", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "186c2253804b0f94a9f79fccb625946dc46c490624dd65312f0daef973a3b538"}
{"doc_id": "eanm__v00000000", "chunk_id": "000044", "text": "derline–malignant and benign lesions. Furthermore, even\nafter positive findings when analysing the diagnostic value\nof 2-[18F]FDG PET/CT in ovarian cancer, Fenchel et al.\n[56] and Tanizaki et al. [57] described false-negative and\nfalse-positive results. The false-negative patients appeared\nbecause of the absent or low 2-[18F]FDG accumulation\nTable 2   Clinical indications, levels of evidence and grade of recom-\nmendation for 2-[18F]FDG PET/CT in ovarian cancer\nClinical indication of 2-[18F]FDG\nPET/CT in ovarian cancer\nLevel of evidence\nGrade of\nrecommen-\ndation\nInitial diagnosis and staging\nin patients presenting with a\npelvic mass\nIII\nGrade C\nPrognostic value\nI\nGrade B\nTreatment planning\nIV\nGrade C\nTherapy assessment\nII\nGrade B\nRelapse detection\nI\nGrade A\n3294\nEuropean Journal of Nuclear Medicine and Molecular Imaging  (2021) 48:3286–3302\n1 3", "section": "Delineation of MATVs may be affected by similar errors", "page_from": 9, "page_to": 9, "display_name": "EANM", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "9f3e63bb00d67b8ba0f16ebb81f68ca9cb9eb50cd5e51f19a1cb1ce7e42b0a92"}
{"doc_id": "eanm__v00000000", "chunk_id": "000045", "text": "in early tumours and clear-cell, mucinous and cystic car-\ncinomas (compared with serous carcinoma and epithelial\ncarcinoma) [58–60]. The false-positive results commonly\nappeared associated to 2-[18F]FDG accumulation in benign\nconditions, such as cystadenomas, endometriomas and acute\ninflammatory processes, or in premenopausal ovaries deriv-\ning from cyclic functional activity changes.\nAs in other fields of oncology, it is a well-known fact\nthat there is an overlap between the degree of 2-[18F]FDG\nuptake in malignant, borderline–malignant and benign\nlesions. Thus, 2-[18F]FDG PET/CT has a good diagnos-\ntic accuracy in discriminating ovarian cancer from benign\ntumours, this not being the case when trying to differentiate\nborderline–malignant from benign tumours because of its\ncomparatively lower diagnostic accuracy in this context [57].\nA meta-analysis including 8 studies and 594 patients\nreported an joint sensitivity and specificity for metastasis of\n0.72 (95% confidence interval [CI] = 0.61–0.81) and 0.93\n(95% CI = 0.85–0.97), respectively [61]. Heterogeneity\nanalysis showed high values both for sensitivity (97.57%)\nand specificity (96.74%). In sensitivity analyses, studies", "section": "Delineation of MATVs may be affected by similar errors", "page_from": 10, "page_to": 10, "display_name": "EANM", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "a0ffb83d58d8c103da325a40cedcecee0b367c81b97be2be19773d73b6635cd4"}
{"doc_id": "eanm__v00000000", "chunk_id": "000046", "text": "(95% CI = 0.85–0.97), respectively [61]. Heterogeneity\nanalysis showed high values both for sensitivity (97.57%)\nand specificity (96.74%). In sensitivity analyses, studies\nusing laparotomy as the gold standard evidenced better\nsensitivity and specificity (0.77, 95% CI = 0.67–0.87, and\n0.96, 95% CI = 0.92–0.99, respectively) than those includ-\ning diagnostic laparoscopy (0.62, 95% CI = 0.46–0.77, and\n0.84, 95% CI = 0.69–0.99, respectively). Better specificity\nwas demonstrated in studies that confirmed surgical find-\nings using pathology (0.95, 95% CI = 0.90–0.99) than in\na study not applying pathology confirmation (0.69, 95%\nCI = 0.24–1.00). Studies with a lower prevalence of the\n2-[18F]FDG-avid subtype showed better specificity (0.97,\n95% CI = 0.94–1.00) than those with a higher prevalence\n(0.89, 95% CI = 0.80–0.97).\nPrognostic value\nLevel of evidence: I\nRecommendation: grade B\nThe assessment of the prognosis is key for patient man-\nagement planning. There is broad evidence confirming the\nprognostic value of 2-[18F]FDG PET/CT in ovarian cancer,\nwith many meta-analyses published in the last years [58,\n62–73]. MTV and TLG from 2-[18F]FDG PET/CT were sig-", "section": "Delineation of MATVs may be affected by similar errors", "page_from": 10, "page_to": 10, "display_name": "EANM", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "b6477e1edbb97c107db7490cf97bc1dd3bccebbb2daba312004f8e748c870061"}
{"doc_id": "eanm__v00000000", "chunk_id": "000047", "text": "prognostic value of 2-[18F]FDG PET/CT in ovarian cancer,\nwith many meta-analyses published in the last years [58,\n62–73]. MTV and TLG from 2-[18F]FDG PET/CT were sig-\nnificant prognostic factors in these patients. Although there\nwas clinical heterogeneity and methodological differences\nbetween studies, patients with a high MTV or TLG present\nmore risk of disease progression or death [61].\n2-[18F]FDG PET/CT is a diagnostic procedure useful for\nthe accurate detection of not previously known metastases.\nMoreover, it gives an insight into tumour biology and behav-\niour and, thus, the potential influence of these aspects on\nthe prognosis. Several studies have evidenced significant\nassociations between primary tumour SUVmax and FIGO\nstage, pathology (serous/non-serous carcinoma), metastatic\nlymphadenopathies and a bad prognosis with a significantly\nworse overall survival rate between cases with high and low\nprimary tumour SUVmax [63, 74, 75]. Mucinous and clear-\ncell ovarian cancer shows a significantly lower SUVmax\nthan in serous carcinomas [63]. The explanation for this can\nbe found in the pathophysiology, based on different glucose", "section": "Delineation of MATVs may be affected by similar errors", "page_from": 10, "page_to": 10, "display_name": "EANM", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "90ab126b06907356d6f4601e2d76e66dab555ed1d7ee13da6b7e337fb3da4839"}
{"doc_id": "eanm__v00000000", "chunk_id": "000048", "text": "cell ovarian cancer shows a significantly lower SUVmax\nthan in serous carcinomas [63]. The explanation for this can\nbe found in the pathophysiology, based on different glucose\ntransporter concentrations in the different tumour subtypes.\nCho et al. [52] described a strong association between mem-\nbrane GLUT-1 overexpression in the primary tumour and\nbad overall survival and also ovarian cancer aggressiveness.\nOther prognostic factors prior to treatment are volumetric\nmetabolic PET parameters, such as MTV and TLG [64].\nChung et al. [76] observed that MTV and TLG were\nstatistically significant independent prognostic factors in\novarian cancer associated with progression-free interval.\nLee et al. [64] showed that TLG was an independent prog-\nnostic factor for disease progression following cytoreduc-\ntive surgery. Gallicchio et al. reported similar data for MTV\n[77]. Risum et al. [70] showed that stage IIIC/IV disease\non 2-[18F]FDG PET/CT was associated with worse overall\nsurvival and proposed using 2-[18F]FDG PET/CT criteria\nfor referring ovarian cancer patients to neoadjuvant chemo-\ntherapy before surgery. Therefore, 2-[18F]FDG PET/CT", "section": "Delineation of MATVs may be affected by similar errors", "page_from": 10, "page_to": 10, "display_name": "EANM", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "cb8c88e3ff35da5a13dff0ec582a6ee47bbf6ca06110c571c3360183645f99e5"}
{"doc_id": "eanm__v00000000", "chunk_id": "000049", "text": "survival and proposed using 2-[18F]FDG PET/CT criteria\nfor referring ovarian cancer patients to neoadjuvant chemo-\ntherapy before surgery. Therefore, 2-[18F]FDG PET/CT\nhelps finding previously unknown metastatic lesions but also\nhelps evaluating the risk of residual cancer following surgi-\ncal treatment, in summary, improving patient management.\nTreatment planning\n–\t Evaluation of tumour resectability\n–\t Predictive value before upfront debulking surgery or\ninterval debulking surgery\n–\t Predictive value before chemotherapy\nLevel of evidence: IV\nRecommendation: grade C\nIn these clinical situations, the available evidence is lim-\nited [78–85], including retrospective studies. In women with\nadvanced stage ovarian cancer, no firm conclusions can be\ndrawn regarding the replacement of diagnostic CT by 2-[18F]\nFDG PET/CT or contrast-enhanced or diffusion-weighted\n(DW) MRI to assess incomplete debulking surgery. 2-[18F]\nFDG PET/CT and MRI are commonly available in hospitals,\nand they suggested there was a high specificity and moderate\nsensitivity to assess incomplete debulking. Potential advan-\ntages included the ability of 2-[18F]FDG PET/CT to detect", "section": "Delineation of MATVs may be affected by similar errors", "page_from": 10, "page_to": 10, "display_name": "EANM", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "871fa62be77f21a82bff9be237f94aad6713a52b968ed93c011064c6491bbcd9"}
{"doc_id": "eanm__v00000000", "chunk_id": "000050", "text": "and they suggested there was a high specificity and moderate\nsensitivity to assess incomplete debulking. Potential advan-\ntages included the ability of 2-[18F]FDG PET/CT to detect\nextra-abdominal (distant) disease and the soft tissue contrast\nof MRI for (small) lesion detection. Importantly, the level of\nevidence is insufficient to advise routine addition of 2-[18F]\nFDG PET/CT or MRI to clinical practice [84].\nAs mentioned above in the “Treatment” section, there\nhas been a paradigm change with regard to nodal staging.\n3295\nEuropean Journal of Nuclear Medicine and Molecular Imaging  (2021) 48:3286–3302\n123456789)\n1 3", "section": "Delineation of MATVs may be affected by similar errors", "page_from": 10, "page_to": 10, "display_name": "EANM", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "9809f43a2315cc2446a4c56d4c366ac7fc663b1ad94d7425a14ded58be266c7f"}
{"doc_id": "eanm__v00000000", "chunk_id": "000051", "text": "First, in early-stage ovarian carcinoma, the indication for\nstaging surgery may be questioned, whereas when referring\nto lymph node dissection for restaging purposes, the proce-\ndure may be avoided if the nodal status does not alter patient\nmanagement [29, 30]. Second, in the case of serous bor-\nderline ovarian tumours (sBOTs) with peritoneal implants,\nthere is no proven benefit of lymphadenectomy in stage II/\nIII sBOTs [29, 30]. Third, in patients with advanced ovarian\ncancer (AOC), after intraabdominal macroscopically com-\nplete resection and presenting normal lymph nodes both\nbefore and during surgery, systematic pelvic and paraaortic\nlymphadenectomy did not correlate with better overall or\nprogression-free survival than no lymphadenectomy but was\nassociated with an increased incidence rate of postsurgical\nmorbidity and complications [32], as well as increased costs.\nBecause of this, to ameliorate patient selection for those who\nwill benefit from lymphadenectomy, a presurgical imaging\ntest providing an accurate nodal staging was proposed [86].\nMany studies have shown 2-[18F]FDG PET/CT has a bet-\nter diagnostic performance in detecting metastatic lymph", "section": "Delineation of MATVs may be affected by similar errors", "page_from": 11, "page_to": 11, "display_name": "EANM", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "fdcda970fc598ad72261e4318b8bc1573a1f6683e1d8bfe91fac329c4563b8b0"}
{"doc_id": "eanm__v00000000", "chunk_id": "000052", "text": "test providing an accurate nodal staging was proposed [86].\nMany studies have shown 2-[18F]FDG PET/CT has a bet-\nter diagnostic performance in detecting metastatic lymph\nnodes compared with ceCT only [87]. A meta-analysis by\nYuan et al. [88] (including 882 patients from 18 studies)\nshowed that 2-[18F]FDG PET/CT had better accuracy than\nboth ceCT and MR in detecting metastatic lymphadenopa-\nthies, with sensitivity and specificity values of 73% and 96%\nfor 2-[18F]FDG PET/CT, 42% and 95% for ceCT and 54%\nand 88% for MRI, respectively, with significant differences\nreached only in sensitivity. Signorelli et al. [86] confirmed\nthe previous results. These studies evidence that 2-[18F]FDG\nPET/CT may be a precise imaging test for selecting patients\ncould benefit from systematic lymphadenectomy. Thus, the\nhigh negative predictive value (NPV) may avoid lymphad-\nenectomy in many cases, reducing to a minimum the surgical\ncomplications.\nIt is known that 2-[18F]FDG PET/CT can ameliorate pre-\nsurgical staging by detecting extra-abdominal spread not\ndetected by radiological procedures [51, 89, 90] including\nlymphadenopathies situated outside the abdominopelvic area", "section": "Delineation of MATVs may be affected by similar errors", "page_from": 11, "page_to": 11, "display_name": "EANM", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "b344f6d029c9c99264ec8b94bd3f01995f2a0e7cdc83f568ebe1955fb59b9f23"}
{"doc_id": "eanm__v00000000", "chunk_id": "000053", "text": "surgical staging by detecting extra-abdominal spread not\ndetected by radiological procedures [51, 89, 90] including\nlymphadenopathies situated outside the abdominopelvic area\nas well as unsuspected extraovarian tumours [49, 51]. Loca-\ntions of metastatic lesions found by 2-[18F]FDG PET/CT\nwere predominantly supradiaphragmatic [90]. Moreover, the\npresurgical staging of advanced disease with PET has evi-\ndenced that up-staging from stage III to IV happens in a high\nproportion of cases [91]. In addition, 2-[18F]FDG PET/CT\nimproves the identification of stage III/IV patients for whom\ncomplete debulking is not possible. There is evidence that\nstage IV cases with diverse volumes of residual disease may\nhave similar evolutions; thus, an early detection of stage IV\ncan be useful for changing the therapeutic approach.\nWith regard to 2-[18F]FDG PET/CT and its indication\nor not for assessing peritoneal carcinomatosis when stag-\ning ovarian cancer, there is certain controversy, but several\nstudies have reported promising results. ceCT is the most\naccurate. 2-[18F]FDG PET/CT seems to have an acceptable\ndiagnostic accuracy for tumour implants greater than 5 mm,", "section": "Delineation of MATVs may be affected by similar errors", "page_from": 11, "page_to": 11, "display_name": "EANM", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "a0c0d7607ca76582153d9925a665c38bd388c781520fee673ae2bdde69604906"}
{"doc_id": "eanm__v00000000", "chunk_id": "000054", "text": "studies have reported promising results. ceCT is the most\naccurate. 2-[18F]FDG PET/CT seems to have an acceptable\ndiagnostic accuracy for tumour implants greater than 5 mm,\nalthough in any case a detailed review of the CT images of\nthe 2-[18F]FDG PET/CT should be done, comparing with\nprevious CT images, for an adequately evaluation of the sta-\ntus of the disease in the peritoneum. In cases with peritoneal\ncarcinomatosis with evident 2-[18F]FDG uptake, an apron\nsign or shield sign can be detected, appearing as 2-[18F]FDG\nuptake along the anterior abdomen (on occasions related to\nincreased peritoneal thickening or omental fat stranding on\nceCT) [92].\nTherapy assessment\nLevel of evidence: II\nRecommendation: grade B\nThere are few clinical trials evaluating the role of 2-[18F]\nFDG PET/CT in the assessment of therapy response. Chun-\ndury and colleagues [80] explored the role of 2-[18F]FDG\nPET/CT in order to evaluate the efficacy of intensity-modu-\nlated radiation therapy (IMRT) in women treated for recur-\nrent ovarian cancer. Among 17 patients, 11 showed a par-\ntial metabolic response, while in six a complete metabolic\nresponse was observed. Furthermore, among 11 patients", "section": "Delineation of MATVs may be affected by similar errors", "page_from": 11, "page_to": 11, "display_name": "EANM", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "77e12d0396e2b283e6b91f60af6fd2254fb10a7dfbf431984b4c80e00cf27db9"}
{"doc_id": "eanm__v00000000", "chunk_id": "000055", "text": "rent ovarian cancer. Among 17 patients, 11 showed a par-\ntial metabolic response, while in six a complete metabolic\nresponse was observed. Furthermore, among 11 patients\nwith partial metabolic response, in only two cases recurrence\nwas observed at the site of IMRT, while of the 6 patients\nwith complete metabolic response recurrence was found in\nonly one woman at the site of IMRT.\nIn three studies, 2-[18F]FDG PET/CT was used to assess\nneoadjuvant chemotherapy response [85, 93, 94]. Vallius\net al. [85] reported that patients with normalization of\nSUVmax after 3 courses had higher probabilities to benefit\nfrom additional 3 courses. The study from Hynninen et al.\n[93] did not confirm the ability of 2-[18F]FDG PET/CT to\ndistinguish responders from non-responders compared to\nmorphological imaging, due to residual 2-[18F]FDG activ-\nity. In fact although 2-[18F]FDG uptake at the end of the\ntreatment tended to be confirmed in case of relapse, this\nresidual activity was observed even in RECIST complete\nresponders. In another study, Vallius et al. [94] described\nthat a decrease in MATV < 85% permitted identifying cases\nwith stable or progressive disease (as per RECIST 1.1) after", "section": "Delineation of MATVs may be affected by similar errors", "page_from": 11, "page_to": 11, "display_name": "EANM", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "531e38228c81fa5c6bcad48bf9269bd6b474fc2975d547d8499ed8db4bc30e82"}
{"doc_id": "eanm__v00000000", "chunk_id": "000056", "text": "responders. In another study, Vallius et al. [94] described\nthat a decrease in MATV < 85% permitted identifying cases\nwith stable or progressive disease (as per RECIST 1.1) after\nneoadjuvant chemotherapy for inoperable EOC with a sen-\nsitivity and specificity of 70% and 78%, respectively, and\nthat MTV decrease was associated with PFS. More recently,\nan ancillary PET study from the CHIVA trial [95] demon-\nstrated that 2-[18F]FDG PET/CT using EORTC or PER-\nCIST criteria was useful to evaluate early tumour response\nand predict second-look surgery outcome, PFS and OS. In\nthis study, neither MATV nor TLG was useful in predict-\ning survival.\n3296\nEuropean Journal of Nuclear Medicine and Molecular Imaging  (2021) 48:3286–3302\n1 3", "section": "Delineation of MATVs may be affected by similar errors", "page_from": 11, "page_to": 11, "display_name": "EANM", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "324f2a09c68521775e7c7678c6973c437524d90a0574b5605a70ed836f31cdc5"}
{"doc_id": "eanm__v00000000", "chunk_id": "000057", "text": "Relapse detection\n•\t Non-conclusive radiological imaging\n•\t Negative radiological imaging with increased tumour\nmarkers\nLevel of evidence: I\nRecommendation: grade A\nThere is broad evidence regarding this indication\n[96–100]. Several meta-analyses have reported the high\nperformance of 2-[18F]FDG PET/CT in suspected recurrent\ndisease with a better diagnostic accuracy than radiological\nimaging, especially in the context of increasing CA-125\nserum levels [26, 88, 101]. Furthermore, ESMO guidelines\non ovarian cancer indicate that 2-[18F]FDG PET/CT may\nindicate locations of disease not detected on CT. The main\nrole of 2-[18F]FDG PET/CT is to contribute in selecting\npatients for secondary debulking surgery, by excluding cases\nwith additional sites of disease not detected on CT and not\ntreatable with cytoreduction [7].\nIncreased serum CA-125 is very accurate for indicating\nthat there is active recurrent disease. Nevertheless, normal\nserum CA-125 does not permit excluding a relapse. Thus,\nthere is evidence that in ovarian cancer patients in com-\nplete clinical remission, a progressive low-level elevation in\nserum CA-125 (staying under the upper normal threshold) is", "section": "Relapse detection", "page_from": 12, "page_to": 12, "display_name": "EANM", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "73be0733e22b9ecda1b6d66de5bae23eae925a1a827661f9ff51e4ead9aad957"}
{"doc_id": "eanm__v00000000", "chunk_id": "000058", "text": "there is evidence that in ovarian cancer patients in com-\nplete clinical remission, a progressive low-level elevation in\nserum CA-125 (staying under the upper normal threshold) is\nhighly predictive of relapse [102]. The role of 2-[18F]FDG\nPET/CT in these cases with a low-level elevation of serum\nCA-125 has been studied with promising results [103–106].\nThe available studies confirm the utility of 2-[18F]FDG\nPET/CT to change treatment management, on one hand\nguiding the indications to otherwise unplanned therapies\nand, on the other hand, saving from performing previously\nplanned diagnostic procedures, with values ranging between\n30 and 57% [107–110]. The available reports coincide with\nfindings from the US National Oncology PET Registry,\nshowing that changes in management were done in 38% to\n45% of cases who were restaged with 2-[18F]FDG PET/CT\n[111, 112].\nFollow‑up\nFollow-up is not indicated unless there is suspicion of\nrelapse and negative radiological imaging [29, 30].\nConclusion\n2-[18F]FDG PET/CT is an established imaging technique\nin oncology in general and in gynaecological cancer in\nparticular. Given the high incidence and aggressiveness", "section": "Relapse detection", "page_from": 12, "page_to": 12, "display_name": "EANM", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "22ee4e2da0db3765477540870b1a1981db606007c1ce0507654892605121c42f"}
{"doc_id": "eanm__v00000000", "chunk_id": "000059", "text": "Conclusion\n2-[18F]FDG PET/CT is an established imaging technique\nin oncology in general and in gynaecological cancer in\nparticular. Given the high incidence and aggressiveness\nof ovarian cancer, a guideline focusing on the role of\n2-[18F]FDG PET/CT in this tumour was developed. The\nevidence available in the literature was reviewed for each\nclinical indication, assigning a level of evidence and a\nrecommendation grade following the NICE adaptation. In\nconclusion, 2-[18F]FDG PET/CT is most useful in relapse\ndetection (level of evidence I, grade of recommendation\nA), followed by its prognostic value (level of evidence I,\ngrade of recommendation B). There is less evidence for\ntherapy assessment (level of evidence II, grade of recom-\nmendation B) and very scarce or low quality evidence for\ninitial diagnosis and staging in patients presenting with a\npelvic mass (level of evidence III, grade of recommenda-\ntion C) and treatment planning (level of evidence IV, grade\nof recommendation C). Finally, multidisciplinary collabo-\nration is especially important to obtain the best possible\noutcome, as well as weighting the need for personalizing\ndiagnosis and therapy to the individual patient.", "section": "Relapse detection", "page_from": 12, "page_to": 12, "display_name": "EANM", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "e08a5ff6321cbc39406169be6bf276d6d16b09ec0ca23ff2b5f3ac9a0a8ce3cb"}
{"doc_id": "eanm__v00000000", "chunk_id": "000060", "text": "ration is especially important to obtain the best possible\noutcome, as well as weighting the need for personalizing\ndiagnosis and therapy to the individual patient.\nAcknowledgements  The authors are grateful to the International\nAtomic Energy Agency (IAEA) for scientific and logistic support. They\nalso appreciate the contribution of the EANM National Societies of\nNuclear Medicine and EANM committees who reviewed the guideline.\nDeclarations \nEthics approval  This article does not contain any studies with human\nparticipants performed by any of the authors.\nConflict of interest  The authors declare no competing interests.", "section": "Relapse detection", "page_from": 12, "page_to": 12, "display_name": "EANM", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "f895146a443b13fc695ed9de66c4ea94375b6881e786e6098ff9451f6821e1af"}
